Answers are grounded in this paper and cite their sources.
Research identifies TWSG1 variation predicting ustekinumab response in inflammatory bowel disease, suggesting a targeted treatment approach.
TWSG1 SNV was associated with early and persistent clinical remission in ustekinumab-exposed IBD patients. Wild-type carriers who did not achieve remission were not rescued with high-dose treatment.
No takes yet. Share an insight, caveat, or question.
Alkhalifa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: